SequelSEC

agilon health, inc. AGL

Services-Misc Health & Allied Services, NEC · CIK 0001831097 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$5.93B
Fiscal year ended 2025-12-31
Operating income
-$463.24M
Fiscal year ended 2025-12-31
Free cash flow
-$119.00M
Fiscal year ended 2025-12-31

agilon health, inc. (AGL) reported revenue of $5.93B and net income of -$391.35M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from agilon health, inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Misc Health & Allied Services, NEC.

Income

agilon health, inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue$5.93B$6.06B$4.32B$2.39B$1.52B$1.22B$794.41M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$463.24M-$292.13M-$232.13M-$105.38M-$372.24M-$56.67M-$106.57M
Net income-$391.35M-$260.15M-$262.60M-$106.55M-$406.49M-$60.05M-$282.59M
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 413.97Mshares 410.97Mshares 408.92Mshares 408.15Mshares 372.93Mshares 323.46MUnavailable
Pretax income-$404.10M-$248.83M-$194.46M-$90.67M-$382.98M-$62.34M-$114.69M
Income tax expense$1.25M$1.45M$791.00K$1.64M$886.00K$865.00K-$232.00K
Diluted EPSUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$238.54M$268.91M$285.76M$207.79M$427.50M$137.29M$122.83M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

agilon health, inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Cash & equivalents$173.71M$188.23M$107.57M$465.30M$1.04B$106.80MUnavailable
Total assets$1.27B$1.73B$1.74B$1.70B$1.59B$446.36MUnavailable
Current assets$1.10B$1.46B$1.48B$1.45B$1.37B$294.20MUnavailable
Total liabilities$1.14B$1.26B$1.08B$656.86M$494.66M$421.59MUnavailable
Current liabilities$1.08B$1.15B$977.16M$535.09M$356.96M$266.84MUnavailable
Total equity incl. NCI$126.73M$470.95M$661.02M$1.04B$1.09B-$284.73M-$232.03M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable$0$309.50MUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$673.79M$1.02B$942.46M$492.36M$293.41M$144.56MUnavailable
Goodwill$0$24.13M$24.13M$2.51M$41.54M$41.54MUnavailable
Long-term debt$15.75M$34.90M$32.31M$38.48M$43.40M$64.66MUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

agilon health, inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Operating cash flow-$105.76M-$57.78M-$156.20M-$130.81M-$148.16M-$53.20M-$103.86M
Capital expenditures$13.24M$13.25M$15.83M$15.43M$6.56M$1.78M$2.89M
Investing cash flow$88.61M$139.89M-$44.02M-$444.39M-$90.51M$22.07M-$5.06M
Financing cash flow-$2.99M-$2.58M-$193.13M$28.06M$1.15B$24.62M$176.30M
Net change in cash-$20.15M$79.53M-$393.35MUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$49.12M$50.66M$69.50M$28.38M$292.39M$6.69M$5.22M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailable$200.00MUnavailableUnavailable$6.70MUnavailable
Depreciation & amortization$28.59M$24.46M$20.16M$13.77M$14.67M$14.10M$41.41M

Derived

agilon health, inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Free cash flow-$119.00M-$71.03M-$172.03M-$146.23M-$154.72M-$54.98M-$106.75M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-7.8%-4.8%-5.4%-4.4%-24.5%-4.7%-13.4%
FCF margin-2.0%-1.2%-4.0%-6.1%-10.2%-4.5%-13.4%
SBC / revenue0.8%0.8%1.6%1.2%19.2%0.5%0.7%
Current ratio1.02x1.27x1.51x2.71x3.83x1.10xUnavailable
Revenue YoY growth-2.1%40.4%80.7%57.0%24.9%53.4%Unavailable
Net margin-6.6%-4.3%-6.1%-4.5%-26.7%-4.9%-35.6%
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenue0.2%0.2%0.4%0.6%0.4%0.1%0.4%
Long-term debt / equity0.12xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open AGL in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-02-25View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-04View SEC filing
10-Q · Filed 2025-05-06View SEC filing

Companies in the same industry

BRTX CCEL DVA MGRX MRAI PARK PFHO PGNY SHC VMD

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.